icon-folder.gif   Conference Reports for NATAP  
 
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
 
 
 
Peginterferon Lambda-1A (Lambda) Compared With Peginterferon Alfa-2A (Alfa) in Treatment- Naive Patients With HCV Genotypes 2 or 3: First SVR24 Results From EMERGE Phase IIb
 
 
  Reported by Jules Levin
 
S Zeuzem, S Arora, B Bacon, T Box, M Charlton, M Diago, D Dieterich, R Esteban Mur, G Everson, M Fallon, P Ferenci, R Flisiak, J George, R Ghalib, N Gitlin, A Gladysz, S Gordon, S Greenbloom, T Hassanein, I Jacobson, L Jeffers, K Kowdley, E Lawitz, S Lee, B Leggett, S Lueth, D Nelson, P Pockros, M Rodriguez-Torres, V Rustgi, L Serfaty, M Sherman, M Shiffman, R Sola, M Sulkowski, H Vargas, J Vierling, B Yoffe, L Ishak, D Fontana, D Xu, J Lester, T Gray, A Horga, J Hillson, JC Lopez-Talavera, A Muir, on behalf of the EMERGE Study Group
 
47th EASL Congress, Barcelona, Spain
April 18-22, 2012
Oral Abstract 1435

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif